Actinium Pharma

ACTINIUM PHARMACEUTICALS INC

Actinium Pharmaceuticals

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AGRI

ATNM

ATPC

BJDX

CHGG

CNSP

HPAI

LCID

LUMN

PLTR

RXST

SERV

SMFG

SPWR

TENK

TPET

UPXI

Why Palantir Technologies Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket

wall street ai9

Earnings

Eurozone

Commodities

Intraday Update

VBIV

S&amp;P 500 Down Over 100 Points; Actinium Pharmaceuticals Shares Plunge

Miscellaneous Services

Dow Tumbles 950 Points; ISM Services PMI Surges In July

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharmaceuticals Inc

Press Releases

Actinium Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before May 27, 2025 to Discuss Your Rights - ATNM

Legal

Shareholders that lost money on Actinium Pharmaceuticals, Inc.(ATNM) Urged to Join Class Action – Contact The Gross Law Firm to Learn More

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM

ATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit

Levi & Korsinsky Notifies Shareholders of Actinium Pharmaceuticals, Inc.(ATNM) of a Class Action Lawsuit and an Upcoming Deadline

Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) - May 27, 2025 Deadline to Join – Contact Levi & Korsinsky

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

Kuehn Law Encourages Investors of Actinium Pharmaceuticals, Inc. to Contact Law Firm

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Solaris, Actinium, Bakkt, and SoundHound and Encourages Investors to Contact the Firm

Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) - May 27, 2025 Deadline to Join - Contact The Gross Law Firm

BKKT

SOUN

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

bluebird bio

Celularity

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Fortress Biotech

Forte Biosciences

Gain Therapeutics

Werewolf Therapeutics, Inc. - Common Stock

Werewolf Therapeutics

ImmuCell

Immuneering Corporation - Class A Common Stock

Immuneering

Opus Genetics

Kronos Bio

Lantern Pharma

MAIA Biotechnology

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

Mural Oncology

OKYO Pharma

PepGen

PMV Pharma

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Renovaro

Rein Therapeutics

Shattuck Labs

Xilio Therapeutics

HC Wainwright & Co.

Stephens & Co.

Maxim Group

Cantor Fitzgerald

B. Riley Securities

Screenshot 2024-02-29 at 7.16.11 PM

Biotech

General

COEP

Here&#39;s How Coeptis Therapeutics Is Innovating Cell Therapy Approaches

Comments

Actinium Pharma

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell